Eirini Sachouli
Research Subjects
Eirini Sachouli has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Kitaygorodsky
ProteinQure Inc
1 shared publication - Anita K. Nivedha
Department of Computational & Quantitative Medicine, Beckman Research Institute of the City of Hope, 1500 E. Duarte Road, Duarte, California, 91010, USA
1 shared publication - Aron Broom
ProteinQure Inc
1 shared publication - Ashlin K. Kanawaty
ProteinQure Inc
1 shared publication - Caroline Woffindale1 shared publication
- Ella Halcrow1 shared publication
Latest Publications
- Open Access
Improved De Novo Peptide Binder Design with Target-Conditioned Inverse Folding
Inverse protein folding methods have become central to the computational design of de novo proteins, but existing models struggle when tasked with generating high-affinity peptide binders. By combining peptide-specific finetuning with a novel decoding order strategy, we enhance pocket conditioning and enable more accurate sequence design for peptide-binding interfaces. Our approach delivers gains in computational metrics, increasing sequence recovery and improving in silico binder design success rate by 16% ™ 30%. In vitro validation finds that our method greatly improves the success rate of designing novel peptide agonists of the OPRM1 receptor, generating at least twice as many top-ranking agonists as the prevailing standard method ProteinMPNN.
Open AccessImproved De Novo Peptide Binder Design with Target-Conditioned Inverse Folding
Inverse protein folding methods have become central to the computational design of de novo proteins, but existing models struggle when tasked with generating high-affinity peptide binders. By combining peptide-specific finetuning with a novel decoding order strategy, we enhance pocket conditioning and enable more accurate sequence design for peptide-binding interfaces. Our approach delivers gains in computational metrics, increasing sequence recovery and improving in silico binder design success rate by 16% ™ 30%. In vitro validation finds that our method greatly improves the success rate of designing novel peptide agonists of the OPRM1 receptor, generating at least twice as many top-ranking agonists as the prevailing standard method ProteinMPNN.